Germany Actinic Keratosis Therapeutic Market Analysis

Germany Actinic Keratosis Therapeutic Market Analysis


$ 3999

The Germany Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 3.10%, rising from $249 Mn in the year 2022 reaching $318 Mn by the year 2030. The rising incidence of actinic keratosis, improvements in treatment options, rising public awareness and screening programs, encouraging government initiatives, technological advancements, an aging population, market competition, and patient preferences are the factors driving the Germany Actinic Keratosis Therapeutic Market. The key players in the Germany Actinic Keratosis Therapeutic Market include Bayer, Galderma, Pierre Fabre, Chemiplastics, Oncopharma, Aclaris Therapeutics, Varens, Photocure, Meda Pharma etc.

ID: IN10DEPH422 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Netal Patel

Buy Now

Germany Actinic Keratosis Therapeutic Market Executive Summary

The Germany Actinic Keratosis Therapeutic Market is at around US $249 Mn in 2022 and is projected to reach US $318 Mn in 2030, exhibiting a CAGR of 3.10% during the forecast period

Actinic Keratosis (AK) is a common skin disorder that appears when scaly, sun-damaged skin cells accumulate on sun-exposed parts of the skin. It is more common in those with light skin and can be brought on by long-term exposure to the sun, which can result in the development of skin cancers such as squamous cell carcinoma. Techniques such as cryotherapy, which involves freezing the afflicted skin to remove the top layers of skin cells, and curettage, which includes scraping the affected skin to remove the top layers of skin cells, are available as treatments for AK. Surgical removal or topical therapies, such as laser resurfacing and drugs like calcipotriol, fluorouracil, and tretinoin

In Germany, the prevalence of AK ranges from 2.7% to 7.4% and rises sharply with age. Men have a larger prevalence risk (3.9%) than women have (1.5%). Lighter skin tones, sun exposure (especially from childhood sunburns), and male gender all have an impact on this. Given that AK is more frequent among older people, the aging of the German population may potentially increase the need for therapy. The rising incidence of actinic keratosis, rising public awareness, encouraging government initiatives, technological advancements and patient preferences are the factors driving the Germany Actinic Keratosis Therapeutic Market

Bayer, Galderma, Pierre Fabre, Chemiplastics, Oncopharma, Aclaris Therapeutics, Varens, Photocure, Meda Pharma, and other major players producing therapeutics for AK are present in the German market.

Germany Actinic Keratosis Therapeutics Market Report 2022 to 2030

Market Dynamics

Market Growth Drivers

Several factors contribute to the growth of the Actinic Keratosis Therapeutic Market in Germany. Market expansion is propelled by continuous research and development, resulting in more effective treatments for AK, with innovative therapies gaining popularity among healthcare providers and patients due to improved efficacy and safety profiles

The presence of key market players, the introduction of innovative therapies, and favourable reimbursement policies also play pivotal roles in driving market expansion. Competition among pharmaceutical companies, coupled with strategic partnerships for the development and marketing of AK therapies, stimulates both market growth and innovation

With an aging population, more people in Germany are approaching the peak risk age for AK, which is over 50. The development of AK is influenced by shifting weather patterns and increased sun exposure from recreational activities. Patient preferences for specific treatment modalities, including factors like convenience, ease of use, and minimal side effects, have a notable impact on market trends

Market Restraints

Even though AK is becoming more well known, some people might not be aware of the illness or how crucial early intervention is. Delays in diagnosis and decreased market demand may result from this. Off-label use of some medications not approved for the treatment of AK may increase competition for AK medicines that are approved. Certain patients can be deterred by the negative effects of a particular therapy or prefer non-invasive alternatives. Cost-effective therapies, such as generic topical creams, may be given preference by healthcare providers and payers over more expensive, more advanced alternatives. This may prevent more expensive but novel treatments from entering the market

Prolonged approval procedures and strict legal requirements: It can take a long time and a lot of money to introduce novel AK treatments to the German market, which discourages some manufacturers from doing so. Regulatory agencies may impose further barriers to market entrance by requiring strong clinical data and proof of cost-effectiveness before authorizing new medicines

Healthcare Policies and Regulatory Landscape

Germany's universal healthcare system, which is founded on the social insurance concept and mandates that everyone have health insurance, is what defines its regulatory environment and healthcare policy. Both employers' and workers' contributions fund the system. Eighty-six percent of people are covered by statutory health insurance, which covers prescription drugs, inpatient and outpatient care, mental health services, and mental health. In Germany, health insurance is required, and non-governmental insurers known as sickness funds are in charge of managing the program. The sixteen state governments of Germany oversee public health services, set hospital capacity, provide funding for hospital improvements, and maintain a decentralized, multi-payer healthcare system. The German Medicines Act (AMG) and European Union laws control the regulatory environment for therapeutics in Germany. Depending on the medicine, the Paul Ehrlich Institute (PEI) or the Federal Institute for Drugs and Medical Devices (BfArM) is the appropriate higher federal authority that must approve medicinal items. German and EU directives, standards, and safety requirements govern the contemporary medical device environment in Germany. In order to sell medical equipment in Germany, one must get a Market Authorization from the Ministry of Health (MoH) in accordance with the Directive

Notable Recent Updates

October 2023, the Gemeinsamer Bundesausschuss (G-BA) expanded reimbursement for Ingenol Mebutate (trade name:Curativo) to include moderate AK lesions on the face and scalp.This opens up a larger patient population for this previously limited therapy.

Competitive Landscape

Key Players

  • Bayer
  • Galderma
  • Pierre Fabre
  • Chemiplastics
  • Oncopharma
  • Aclaris Therapeutics
  • Varens
  • Photocure
  • Meda Pharma
  • LEO Pharma

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Germany Actinic Keratosis Market Segmentation

By Treatment Type

  • Topical Treatment
  • Procedural Modality
  • Photodynamic Therapy
  • Others

By Drug Class

  • Nucleoside Metabolic Inhibitor
  • Immune Response Modifiers
  • NSAIDs
  • Photo enhancer
  • Other Drug Classes

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Disease Type

  • Clinical AK
  • Subclinical AK

By End User

  • Hospitals
  • Private Dermatology Clinics
  • Laser Therapy Centres
  • Cancer Treatment Centres
  • Spas and Rejuvenation Centres
  • Homecare

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 15 January 2024
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up